Log in to post a reply
May 4, 2017 03:51AM
Star, I'm sorry the treatment is failing. I too was on Faslodex and Ibrance and it was failing [after 4+ years on Faslodex]. My MO offered the following options:
- Aromasin/Afinitor (you've already done this)
- A clinical trial of A/A plus Ibrance (there's also one with A/A and ribociclib)
- Stick with Faslodex and Ibrance for a while longer -- basically until the scans get a lot worse.
- Do nothing
I know the last is a scary thought, but he always offers.
First thing you should know is there is never a 'no treatment' arm in a cancer trial. The arms are normally standard of care plus either a placebo or a new medicine. So don't fear trials, but if one is offered you should ask lots of questions and make sure they explain things to your satisfaction. Trials can give you access to investigational drugs but are no guarantee.
Another thing to realize is that when docs give 'chemo' it's not at the same doses that the early stage ladies get. The other thing to think about is that just because you agree to start a treatment, that doesn't mean you've agreed to have the second or third dose. YOU get to decide which meds you are willing to try or tolerate. If you hate how it feels, quit and move on. But yes, you get tied to the cancer center and that's definite ugh.
I chose the trial and am in my third month. The TMs continue to rise but the CT scan looks the same. We'll see. My second choice would have been to hang on with Fas/Palbo for a while. Maybe your PET will look fine and you can also continue for a while.
It's scary to have to change treatment. But. There are a lot of treatments yet to try. Take a look at the list on the main BCO site. If each one of them works for a year, you'll see your grandchildren.
Hang in there and many hugs to you.
4/20/2008, IDC, Right, 4cm, Stage IIIA, Grade 2, 1/15 nodes, ER+/PR+, HER2-
2/1/2013, IDC, Stage IV, metastasized to bone, mets, ER+/PR+, HER2-
2/26/2013 Femara (letrozole)
4/21/2013 Faslodex (fulvestrant)
2/24/2016 Ibrance (palbociclib)
6/18/2017 Xeloda (capecitabine)